Aims/hypothesis Fenofibrate is a drug used to treat hyperlipidaemia that works by inhibiting hepatic triacylglycerol synthesis. Sterol regulatory element binding protein-1c (SREBP-1c) is a major regulator of the expression of genes involved in hepatic triacylglycerol synthesis. In addition, endoplasmic reticulum (ER)-bound transcription factor families are involved in the control of various metabolic pathways. Here, we show a novel function for an ER-bound transcription factor, cAMP response element binding protein H (CREBH), in fenofibrate-mediated inhibition of hepatic lipogenesis. Methods The effects of fenofibrate and adenovirus-mediated Crebh (also known as Creb313) overexpression (Ad-Crebh) on hepatic SREBP-1c production and lipogenesis in vitro and in vivo were investigated. We also examined whether downregulation of endogenous hepatic Crebh by small interfering (si)RNA restores the fenofibrate effect on hepatic lipogenesis and SREBP-1c production. Finally, we examined the mechanism by which CREBH inhibits hepatic SREBP-1c production. Results Fasting and fenofibrate treatment induced CREBH production and decreased SREBP-1c levels. Indeed, AdCrebh inhibited insulin-and liver X receptor agonist TO901317-induced Srebp-1c (also known as Srebf1) mRNA expression in cultured hepatocytes. Moreover, increased production of CREBH in the liver of mice following tail-vein injection of Ad-Crebh inhibited high-fat diet-induced hepatic steatosis through inhibition of Srebp-1c expression. The inhibition of endogenous Crebh expression by siRNA restored fenofibrate-induced suppression of Srebp-1c expression and hepatic lipid accumulation both in vitro and in vivo. Conclusions/interpretation These results show that fenofibrate decreases hepatic lipid synthesis through induction of CREBH. This study suggests CREBH as a novel negative regulator of SREBP-1c production and hepatic lipogenesis.
Introduction
Non-alcoholic fatty liver disease, an important hepatic manifestation of metabolic syndrome, is a significant cause of morbidity and mortality in obese individuals with insulin resistance [1, 2] . The onset of fatty liver disease is characterised by increased intracellular triacylglycerol accumulation, causing a condition known as 'fatty liver'. Sterol regulatory element binding protein-1c (SREBP-1c) is a major regulator of the expression of genes involved in hepatic triacylglycerol synthesis [3] . Its role in the development of fatty liver in obese individuals with insulin resistance is now well established. Briefly, hyperinsulinaemia, a hallmark of insulin resistance [4] , stimulates hepatic SREBP-1c production, resulting in increased de novo synthesis of fatty acids (FA) [5] .
The regulation of hepatic SREBP-1c production is largely dependent on nutritional or hormonal stimuli mediated by transcriptional and post-transcriptional mechanisms of gene expression. During feeding, insulin secreted from pancreatic beta cells increases SREBP-1c production through cleavage of precursor SREBP-1c into its active nuclear form and through activation of liver X receptor (LXR) and specific protein 1 (SP1) [6, 7] . Although much is known about how hepatic SREBP-1c is induced by insulin, little is known about how hepatic SREBP-1c is suppressed during fasting, when the effect of insulin is negligible. It is generally accepted that glucagon is the major inhibitor of lipogenesis during the fasting state, because of its activation of the cAMP/protein kinase A pathway [8, 9] . However, the mechanism of action of protein kinase A is not well defined [10] . Moreover, the mechanism by which the absence of insulin suppresses hepatic lipogenesis remains to be elucidated. Pharmacological agents that inhibit transcription factors regulating SREBP-1c production during insulin stimulation may provide effective treatment options for fatty liver disease.
Fenofibrate is used clinically to treat hypertriacylglycerolaemia in patients with metabolic syndrome [11] . Fenofibrate lowers serum triacylglycerol levels through several mechanisms, including increasing VLDL-triacylglycerol clearance and decreasing hepatic triacylglycerol production [12] . Hepatic VLDL production depends on the availability of FA, which is determined by de novo FA synthesis and β-oxidation of FA in the liver [13] . Fenofibrate interferes with FA synthesis and stimulates hepatic fatty acid oxidation, thereby reducing the amount of FA available to the liver for triacylglycerol synthesis [14] [15] [16] . Accumulating evidence indicates that the pharmacological actions of fenofibrate are mediated, at least in part, through the transcriptional regulation of several genes involved in lipid and lipoprotein metabolism [17, 18] . Fenofibrate activates the transcriptional factor peroxisome proliferator-activated receptor α (PPARα), which binds to peroxisome proliferator response elements in the regulatory regions of target genes [19] . PPARα mediates fenofibratemediated regulation of triacylglycerol levels via the transcriptional induction of lipoprotein lipase [20] . However, few studies have investigated the direct role of fenofibrate in SREBP-1c transcriptional regulation during hepatic lipogenesis.
Cyclic AMP response element binding protein H (CREBH) is a membrane-bound transcription factor possessing a basic leucine zipper (bZIP) domain and a domain that resides within the endoplasmic reticulum (ER) [21, 22] . CREBH is cleaved on ER stress and activates the expression of acute response genes [23] . A recent study showed that CREBH is nutritionally regulated [24] . The expression of Crebh (also known as Creb313) mRNA and levels of CREBH protein are high in the fasting mouse liver and are suppressed by re-feeding. The authors also found that feeding-induced suppression of CREBH depends on insulin. Recently, a role for CREBH in triacylglycerol metabolism has been suggested. Genetically CREBH-deficient mice showed higher plasma triacylglycerol concentrations than wild-type mice, and this was due to inefficient triacylglycerol clearance catalysed by lipoprotein lipase [25] . More recently, Zhang et al showed that disruption of CREBH activity leads to massive accumulation of hepatic lipid metabolites and significant increases in plasma triacylglycerol levels in animals fed with an atherogenic high-fat diet (HFD) [26] . However, the role of CREBH in controlling insulin-and LXR-stimulated SREBP-1c production and hepatic lipogenesis by a pharmacological lipid-lowering agent remains to be elucidated. Here, we investigated whether CREBH mediates fenofibrate-induced suppression of hepatic lipogenesis by inhibiting insulin-and LXR-stimulated SREBP-1c production.
Methods

Materials and plasmids
Insulin was provided by Novo Nordisk (Bagsvaerd, Denmark). T0901317 and fenofibrate were purchased from Sigma (St Louis, MO, USA). The SREBP-1c antibody was purchased from BD Biosciences (San Jose, CA, USA), and the actin antibody was from Sigma. Radiochemicals (deoxycytidine 5′-[α-
32 P]triphosphate and adenosine 5′-[γ-32 P]triphosphate) were purchased from Perkin Elmer (Boston, MA, USA). Constructs of human SREBP-1c (also known as SREBF1)-promoter-luciferase (pSREBP-1c[-1516/+40]-luciferase) were kind gifts from L. Cagen (University of Tennessee, TN, USA). A cDNA encoding a constitutively active form of mouse Crebh (also known as Creb313) were provided by H.-S. Choi (Chonnam National University, Gwangju, Korea). Human INSIG2-promoter-reporter constructs was provided by M. Casado (Instituto de Biomedicina de Valencia, Barcelona, Spain).
Cell culture
Rat hepatoma H4IIE and human hepatoma HepG2 cells and mouse hepatocyte AML-12 cells were cultured in medium and infected with Ad-Crebh. For details of cell culture, refer to the electronic supplementary material (ESM) Methods.
Generation of recombinant adenovirus For details of the preparation of recombinant adenovirus, refer to the ESM Methods.
Chromatin immunoprecipitation assay To investigate the binding of protein to promoter, chromatin immunoprecipitation (ChIP) assays were done. For details of the ChIP assay, refer to the ESM Methods.
Animal experiments
Experimental procedure 1 All animal procedures were approved by the local ethics committee and carried out in accordance with institutional guidelines for animal research. Male 8-week-old Sprague-Dawley (SD) rats weighing 250 to 300 g were divided into two groups: fasting and feeding. Animals were fasted for 24 h with free access to water or fasted for 24 h and re-fed during the following 12 h. To demonstrate that feeding-induced hepatic SREBP-1c production is insulin dependent, we performed an additional experiment employing intraperitoneal administration of streptozotocin (STZ; 100 mg/kg) to eliminate endogenous insulin. STZ-treated rats were divided into two groups, fasting and feeding, and subjected to the fasting/feeding protocol described above.
Experimental procedure 2 Male 8-week-old C57BL/6 mice were purchased from Koatech (Kyunggi-Do, Korea) and divided into five groups: (1) Analysis of blood samples Blood levels of glucose, insulin, triacylglycerol and NEFA were measured in overnightfasted mice. For details of the analyses, refer to the ESM Methods.
Genetic analyses in cells and tissues
Quantitative real-time RT-PCR To quantify the DNA in cells and tissues, quantitative real-time RT-PCR was used. For details, refer to the ESM Methods.
Northern blot analysis Northern blot analysis was used to measure mRNA expression. For details, refer to the ESM Methods.
Western blot analysis Protein levels in cells and tissues were examined by western blot analysis. For details of western blotting procedures, refer to the ESM Methods.
In vitro transient transfections and reporter assays Promoter activity was determined by in vitro transfection and luciferase reporter assays. For details, refer to the ESM Methods.
Electrophoretic mobility shift assay DNA-binding activity was measured using an electrophoretic mobility shift assay (EMSA). For details, refer to the ESM Methods.
Statistical analysis
Data were evaluated using ANOVA followed by a post-hoc least-significant-difference test, and expressed as the mean± SEM. Values of p<0.05 were considered statistically significant. All experiments were repeated independently three or more times.
Results
Fasting and fenofibrate treatment increase Crebh expression but decrease Srebp-1c expression
Insulin is one of the most important hormones involved in regulating hepatic lipogenesis. In cultured hepatocytes, insulin increases lipogenesis primarily through the induction of SREBP-1c [27] . In addition, re-feeding after restriction of energy intake increases lipogenesis and SREBP-1c production in the liver [28] . To demonstrate that CREBH production is influenced by insulin, we analysed hepatic Crebh expression during fasting and after re-feeding of control and STZ-induced diabetic rats. Re-feeding after fasting dramatically decreased hepatic Crebh mRNA expression and increased Srebp-1c mRNA expression in control rats (Fig. 1a) . However, after eliminating endogenous insulin by STZ, re-feeding did not suppress Crebh mRNA expression, suggesting that re-feeding-induced suppression of Crebh mRNA expression is mainly mediated by insulin (Fig. 1b ). In addition, no feeding-induced changes in Srebp-1c mRNA expression were observed in the livers of STZ-treated rats (Fig. 1b) . The expression patterns of Srebp1c were opposite to those of Crebh. The effect of insulin on Crebh expression was further confirmed in H4IIE cells. Glucose concentration did not influence Crebh mRNA expression, and insulin treatment significantly reduced Crebh mRNA expression (Fig. 1c) . Collectively, these data suggest that insulin is a major positive regulator of hepatic SREBP-1c production, but a negative regulator of CREBH production. Because fenofibrate is used clinically for lowering hepatic triacylglycerol synthesis, which is induced by hyperinsulinaemia, we evaluated the effect of fenofibrate on CREBH and SREBP-1c production in H4IIE cells. Interestingly, fenofibrate increased Crebh mRNA expression but decreased Srebp-1c mRNA expression (Fig. 1d) . Accordingly, fenofibrate decreased the expression of SREBP-1c target genes, including acetyl-CoA carboxylase (Acc), fatty acid synthase (Fas [also known as Fasn]), and stearoyl-CoA desaturase (Scd [also known as Scd1]) (ESM Fig. 1a ). Moreover, siRNA knockdown of CREBH prevented the inhibitory effect of fenofibrate on Srebp-1c expression (ESM Fig. 1b ). Taken together with the results of the insulin analyses, fenofibrate increases CREBH production but decreases SREBP-1c production, which suggests that Srebp-1c may be a CREBH target gene and that CREBH mediates the effects of fenofibrate on hepatic lipogenesis through inhibition of SREBP-1c production induced by hyperinsulinaemia.
CREBH inhibits insulin-and LXR-stimulated SREBP-1c production in cultured hepatocytes
To elucidate the association between CREBH and insulininduced hepatic lipogenesis, we examined whether adenovirus-mediated overexpression of Crebh inhibits insulin-stimulated SREBP-1c production in cultured hepatocytes. As shown in Fig. 2a ,b, insulin treatment increased Srebp-1c mRNA expression and precursor and nuclear SREBP-1c protein production. However, insulin-stimulated Srebp-1c mRNA expression and SREBP-1c protein production were inhibited by Ad-Crebh in a dose-dependent manner. Accordingly, Ad-Crebh inhibited the insulin-stimulated expression of SREBP-1c-target-gene mRNA (Acc, Fas and Scd; Fig. 2c, d , e). Transient transfection with the human SREBP-1c promoter reporter [29] in HepG2 cells showed that CREBH inhibits insulin-stimulated SREBP-1c mRNA expression at the transcriptional level (Fig. 2f) . Next, to determine if CREBH directly binds to the SREBP-1c promoter to inhibit its activity, we performed a ChIP assay of the putative CREBH binding sites [30] (−400/−394 and −318/−312) in the SREBP1c promoter. CREBH did not bind to these putative binding sites (data not shown). However, it is possible that CREBH directly binds to other regions of SREBP-1c promoter that were not examined in this study. LXR plays a major role in regulating SREBP-1c induction, especially on insulin stimulation [29] . Thus, we examined whether CREBH inhibits LXR-stimulated SREBP-1c production. Indeed, Ad-Crebh inhibited TO901317-stimulated Srebp-1c mRNA expression and SREBP-1c protein production in a dose-dependent manner (Fig. 3a, b) . Ad-Crebh also suppressed TO901317-stimulated Acc, Fas and Scd mRNA expression (Fig. 3c, d, e) . To examine the mechanism underlying CREBH-mediated inhibition of LXR activity, we first tested whether Ad-Crebh influenced the abundance of LXR protein. Western blot analysis showed that Ad-Crebh did not decrease LXR protein production (ESM Fig. 2 ). Next, we examined whether CREBH influences LXR transcriptional activity on the SREBP-1c
promoter. Transient transfection with a promoter reporter construct showed that TO901317 induced a marked increase in SREBP-1c promoter activity, which was inhibited by Crebh (Fig. 3f) . Moreover, TO901317 induced an increase in the DNA-binding activity of LXR, which was inhibited by Ad-Crebh in a dose-dependent manner (Fig. 3g) . To further confirm that CREBH inhibits LXR binding to LXR response element within the SREBP-1c promoter, we performed a ChIP assay. In agreement with the EMSA assay, the results showed that TO901317 induced binding of LXR to the proximal region, which contains two LXR-binding sites. Ad-Crebh abolished the DNA-binding activity of LXR to the SREBP-1c promoter (Fig. 3h) .
Fenofibrate inhibits SREBP-1c production through induction of CREBH production Next, we examined whether fenofibrate inhibits SREBP-1c production and whether fenofibrate-induced CREBH production mediates SREBP-1c production. Treatment with fenofibrate for 24 h dose-dependently attenuated insulin-or TO901317-stimulated Srebp-1c mRNA expression (Fig. 4a,  b) and SREBP-1c protein production (Fig. 4c, d ) in H4IIE cells. Fenofibrate also suppressed insulin-and TO901317-stimulated Acc, Fas and Scd mRNA expression (ESM Fig. 3 ). The induction of Crebh expression by fenofibrate was then examined by real-time RT-PCR (ESM Fig. 3 ). To further confirm whether the suppression of Srebp-1c gene expression by fenofibrate is mediated by CREBH, we downregulated endogenous Crebh expression by transfecting H4IIE cells with siRNA Crebh and then treated them with fenofibrate. siRNA Crebh, but not control siRNA, significantly restored fenofibrate-induced suppression of Srebp-1c expression stimulated by TO901317 (Fig. 4e) . Because fenofibrate induces fatty acid oxidation [31] , we investigated whether CREBH mediates the expression of genes related to fenofibrate-induced fatty acid oxidation. The expression of peroxisome proliferator-activated receptor (PPAR)-γ coactivator-1α (Pgc-1α [also known as Ppargc1a]), carnitine palmitoyltransferase 1 (Cpt-1 [also known as Cpt1b]), and Pparα (also known as Ppara) was modestly increased by Ad-Crebh (ESM Fig. 4a ). However, fenofibrate markedly increased the expression of these genes (ESM Fig. 4b) . Moreover, knockdown of CREBH by siRNA induced a ∼25 % reduction in fenofibrate induction of Pgc-1α and Cpt-1 expression, although it significantly blocked fenofibrate-induced Pparα expression (ESM Fig. 4b ). of Insig2 levels, we examined whether fenofibrate and CREBH prevent insulin-suppressed Insig2 expression. As shown Fig. 5a , insulin and Ad-Crebh did not influence Insig1 mRNA expression but fenofibrate markedly increased Insig1 expression; INSIG1 is dissociated from SREBP-2 chaperone (SCAP)-SREBP-2 under the conditions of sterol depletion, consequently causing SCAP-SREBP-2 complex transportation from the ER to the Golgi. In contrast, insulin decreased but fenofibrate and Ad-Crebh increased Insig2 mRNA expression levels (Fig. 5b) . Therefore, we further examined whether siRNA knockdown of endogenous INSIG2 blocked the suppression of Srebp-1c expression induced by CREBH and fenofibrate. The results showed that Insig2 siRNA markedly inhibited endogenous Insig2 expression, and knockdown of INSIG2 significantly abolished Ad-Crebh-and fenofibratemediated suppression of insulin-stimulated Srebp-1c expression (Fig. 5c, d ). To determine whether expression of Insig2 was transcriptionally regulated by CREBH, we next examined the effects of CREBH on INSIG2 promoter activity. Indeed, a transient transfection study with INSIG2 promoter luciferase [32] showed that Crebh markedly increased INSIG2 promoter (−859/−11 construct) activity, but this activation was markedly attenuated by truncation at −688 bp of the INSIG2 promoter, suggesting that CREBH mainly acts on the region between 5 ). These results suggest that fenofibrate and CREBH retained SREBP-1c in the ER membrane. However, in addition to the increase in Insig1 expression, the effect of fenofibrate on INSIG2 production was much greater than that of Ad-Crebh, suggesting a CREBHindependent pathway. CREBH reduces hepatic lipid accumulation and SREBP-1c production and mediates fenofibrate inhibition of hepatic lipid accumulation in HFD-fed mice Finally, we examined whether CREBH decreases hepatic lipogenesis and mediates fenofibrate-suppressed hepatic lipogenesis in HFD-fed mice. Histological examination showed that hepatocytes of HFD-fed mice were distended by large cytoplasmic lipid droplets. This change in cellular morphology was nearly completely prevented by the overexpression of Crebh and fenofibrate treatment (Fig. 6a) . Both the overexpression of Crebh and fenofibrate treatment significantly decreased hepatic fat accumulation and plasma triacylglycerol levels compared with mice infected with an adenovirus encoding green fluorescent protein (GFP; Fig. 6b, c) . Moreover, downregulation of endogenous Crebh by Ad-siRNA Crebh significantly blocked fenofibratesuppressed hepatic lipid accumulation and plasma triacylglycerol levels in HFD-fed mice (Fig. 6b,c) . Consistent with the histological examination, both Ad-Crebh and fenofibrate reduced Srebp-1c expression but increased Insig2 expression (Fig. 6d, e) . Moreover, the effects of fenofibrate on hepatic Srebp-1c and Insig2 expression were abolished by Ad-siRNA Crebh (Fig. 6d, e) . Fenofibrate treatment increased Crebh expression, but Ad-siRNA Crebh suppressed fenofibrate-induced Crebh expression to basal levels (Fig. 6f) . Because CREBH controls the expression of genes involved in gluconeogenesis, we wanted to know whether fenofibrate treatment influences other metabolic variables. Plasma glucose, insulin and NEFA levels were lower and insulin sensitivity (IPGTT) was higher in the fenofibratetreated group than in the control HFD group. Serum cholesterol levels were not different between the groups (ESM Fig. 6 ).
Discussion
In the present study, we found that fasting and fenofibrate treatment induced CREBH production, while feeding and insulin treatment decreased CREBH production. Interestingly, production of SREBP-1c, which was upregulated by feeding but inhibited by fenofibrate, showed the opposite effects to those of CREBH. Fenofibrate treatment and adenovirus-mediated overexpression of Crebh inhibited insulin-and LXR agonist TO901317-stimulated Srebp-1c mRNA expression in cultured hepatocytes. Moreover, overexpression of Crebh in the liver of mice mediated by tailvein injection of Ad-Crebh inhibited hepatic steatosis through inhibition of SREBP-1c induction. The inhibition of endogenous Crebh expression by siRNAs markedly abolished fenofibrate-induced suppression of Srebp-1c expression and hepatic lipid accumulation. These results show that fenofibrate decreases hepatic lipid synthesis through induction of CREBH. Collectively, this study suggests CREBH as a novel negative regulator of hepatic lipogenesis.
Hepatic lipogenesis is regulated by nutritional status [33] . In mammals, fasting decreases and re-feeding increases hepatic lipid synthesis [29] . Insulin is a potent inducer of hepatic lipogenesis during feeding [7, 29] , and this may be transcriptionally mediated by SREBP-1c [28, 34, 35] . In the present study, while Crebh expression was downregulated by feeding, this downregulation was not observed when endogenous insulin production was eliminated by STZ treatment. Moreover, in cultured hepatocytes, Crebh expression was inhibited by insulin treatment. These data indicate that feeding-induced suppression of Crebh expression is regulated by insulin. The expression patterns of insulin-regulated CREBH were opposite to those of SREBP-1c, suggesting that CREBH plays a role in the regulation of SREBP-1c production and hepatic lipogenesis. Indeed, we found that adenovirus-mediated overexpression of Crebh inhibited insulin-stimulated SREBP-1c production.
The role of SREBP-1c in the development of fatty liver in the insulin-resistant state is now well established [36] . Hyperinsulinaemia, a hallmark of insulin resistance, stimulates hepatic Srebp-1c transcription, resulting in increased hepatic fat synthesis and the development of fatty liver. We [37] and others [38] demonstrated the contribution of SREBP-1c to fat accumulation in the insulin-resistant HFD-induced mouse liver [39] . Many studies have focused on searching for molecules that can inhibit SREBP-1c production, thereby preventing the development of fatty liver. For example, metformin and α-lipoic acid prevent hepatic steatosis by inhibiting SREBP-1c production [29, 40] . Fenofibrate has beneficial effects on metabolic syndrome by downregulating multiple target genes involved in the pathogenesis of hepatic steatosis [41] [42] [43] . Recent studies show that fenofibrate induces CREBH production to a level comparable with that observed under fasting conditions [44] . However, the exact molecular mechanism underlying the anti-hepatic steatosis effect of fenofibrate remains unclear. Thus, we aimed to determine the role of fenofibrate-induced CREBH production in the development of hepatic steatosis in mice with HFD-induced insulin resistance. This study showed that adenovirus-mediated overexpression of Crebh in the liver or treatment of fenofibrate prevented HFDinduced hepatic lipid accumulation and inhibited SREBP-1c production. Moreover, inhibition of endogenous Crebh expression by siRNA prevented fenofibrate-induced suppression of hepatic steatosis, suggesting that CREBH mediates the effects of fenofibrate on hepatic lipogenesis and is a potential therapeutic target for the treatment of hepatic steatosis induced by hyperinsulinaemia.
Insulin-induced SREBP-1c production is regulated at the transcriptional level. The major regulators of Srebp-1c expression are LXR and SREBP-1c itself. LXR is a member of a nuclear receptor superfamily that regulates the production of key proteins involved in lipid metabolism [45, 46] . LXR increases Srebp-1c expression, leading to increased hepatic triacylglycerol synthesis [29] . In our study, fenofibrate and Ad-Crebh inhibited LXR-ligand-stimulated SREBP-1c production. An in vitro transient transfection study employing promoter-reporter constructs showed that inhibition of LXR ligand-stimulated SREBP-1c production by CREBH is mediated via the inhibition of LXR activity on the SREBP-1c promoter. In addition to LXR, in response to insulin, SREBP-1c production is also mediated by the cleaved nuclear form of SREBP-1c itself, which mediates transactivation on the SREBP-1c promoter [33] . A study by Yellaturu et al clearly shows that insulin enhances SREBP-1c production by inducing cleavage of precursor SREBP-1c to its nuclear form [34] . In the resting state, the SCAP-SREBP1c complex is localised to the ER by INSIG2. However, in response to stimuli, INSIG2 dissociates from the SCAP-SREBP-1c complex, thereby facilitating transport of the complex to the Golgi where immature SREBP-1c is cleaved to generate the active form of SREBP-1c [34] . Insulin enhances the rate of turnover of Insig2 mRNA, and insulin-induced depletion of Insig2 promotes proteolysis of SREBP-1c, resulting in active SREBP-1c. Our data show that Ad-Crebh and fenofibrate prevent insulin-suppressed Insig2 gene expression. Moreover, knockdown of INSIG2 expression by siRNA abolished Ad-Crebh-and fenofibratemediated suppression of SREBP-1c. Fenofibrate, however, restored insulin-suppressed Insig2 gene expression to a higher level than did CREBH, suggesting a CREBHindependent mechanism. Taken together, the mechanisms by which CREBH influences hepatic lipogenesis and SREBP-1c production are multifactorial. Our data suggest that CREBH mediates fenofibrate-suppressed hepatic lipogenesis by inhibiting LXR-DNA binding to the SREBP-1c promoter and inducing INSIG2-mediated inactivation of SREBP-1c.
As fenofibrate induces the expression of genes involved in fatty acid oxidation by activating PPARα, induction of these genes is thought to be important for the amelioration of hepatic lipid metabolism. Accordingly, the present study showed that fenofibrate markedly increased the expression of genes involved in fatty acid oxidation. However, we found that although Ad-Crebh modestly increased the expression of these genes, the effect was much smaller than that of fenofibrate. Moreover, knockdown of CREBH production with siRNA did not significantly abolish the fenofibrate-mediated induction of these genes, although a reduction in Crebh expression by siRNA tended to decrease the effects of fenofibrate on gene expression. These data suggest that CREBH-mediated effects of fenofibrateinduced inhibition of hepatic steatosis are mainly due to the inhibition of de novo lipogenesis and not to the augmentation of fatty acid oxidation, although CREBH increases the expression of genes responsible for fatty acid oxidation.
In summary, these data indicate a novel role for CREBH in inhibiting hepatic lipogenesis by fenofibrate. Hepatic steatosis is emerging as the most important cause of chronic liver disease associated with the increasing incidence of obesity. Hepatic steatosis can progress to non-alcoholic steatohepatitis, as well as to advanced cirrhosis. Thus, an effective therapy is needed to prevent this condition. In the present study, we showed that fenofibrate-induced CREBH prevents hepatic steatosis in animals with diet-induced insulin resistance. This suggests that CREBH may serve as a therapeutic target for preventing the development of fatty liver disease in patients with insulin resistance. To more clearly elucidate the role of CREBH in hepatic lipid synthesis, it would be useful to generate animals in which Crebh expression in the liver is conditionally knocked out. Education, Science, and Technology and a grant of the Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (A111345).
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